Belite Bio, Inc - American Depositary Shares (BLTE)

The company is now tantalizingly close to commercializing its leading drug candidate.

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the second quarter of 2024.

BLTE stock results show that Belite Bio missed analyst estimates for earnings per share the first quarter of 2024.

Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration of up to $200 million in cash.

The clinical-stage biotech company bounced back from a 52-week low late last week.

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.